PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
29334491-6	2018	At 8 weeks, both AZL-M/CTD FDCs reduced 24-h SBP more than OLM/HCTZ (-26.4 and -27.9 versus -20.7 mmHg; both P < 0.001), and higher proportions in both AZL-M/CTD groups achieved target BP compared with the OLM/HCTZ group (69.4 and 68.9 versus 54.7%, both P < 0.001).	Olmesartan Medoxomil	209-212	CTD	Homo sapiens	17-26
16183779-1	2005	In the present study, we investigated the esterase-like activity of human serum albumin (HSA) and the mechanism by which it hydrolyzes, and thereby activates, olmesartan medoxomil (CS-866), a novel angiotensin II receptor antagonist.	Olmesartan Medoxomil	159-179	albumin	Homo sapiens	74-87
26251572-15	2015	Electrophoretic mobility shift assays of nuclear extracts demonstrated reduced activity of the transcription factor NF-kappaB when treated with olmesartan medoxomil, amlodipine besylate, or their combination, as compared to controls.	Olmesartan Medoxomil	144-164	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	116-125
20177059-8	2010	The recombinant CMBL also converted other prodrugs having the same ester structure as OM, faropenem medoxomil and lenampicillin, to their active metabolites.	Olmesartan Medoxomil	86-88	carboxymethylenebutenolidase homolog	Homo sapiens	16-20
26420482-4	2015	Here, we report the crystal structure of the human AT1R in complex with an inverse agonist olmesartan (Benicar(TM)), a highly potent anti-hypertensive drug.	Olmesartan Medoxomil	103-110	angiotensin II receptor type 1	Homo sapiens	51-55
26423313-7	2015	RESULTS: In the "on olmesartan medoxomil" duodenal biopsies, a significant increase in the numbers of CD8+ cells and the number of cells that are FoxP3+ (a regulatory T-cell marker) are present in the duodenum as compared to the duodenal biopsies from patients who discontinued olmesartan medoxomil.	Olmesartan Medoxomil	20-40	CD8a molecule	Homo sapiens	102-105
26423313-7	2015	RESULTS: In the "on olmesartan medoxomil" duodenal biopsies, a significant increase in the numbers of CD8+ cells and the number of cells that are FoxP3+ (a regulatory T-cell marker) are present in the duodenum as compared to the duodenal biopsies from patients who discontinued olmesartan medoxomil.	Olmesartan Medoxomil	20-40	forkhead box P3	Homo sapiens	146-151
23355126-0	2008	Reduction of Cardiovascular Risk through Angiotensin II Type 1 Receptor Antagonism : Focus on Olmesartan Medoxomil.	Olmesartan Medoxomil	94-114	angiotensin II receptor type 1	Homo sapiens	41-71
18394840-1	2008	An unknown degradation product (DP-1) increased in olmesartan medoxomil (OLM) tablets stored at 40 degrees C/75% r.h., reaching 0.72% after 6 months.	Olmesartan Medoxomil	73-76	transcription factor Dp-1	Homo sapiens	32-36
18547134-1	2008	Olmesartan medoxomil (Olmetec, Benicar) is an angiotensin II type 1 (AT(1)) receptor antagonist (angiotensin receptor blocker [ARB]) that inhibits the actions of angiotensin II on the renin-angiotensin-aldosterone system, which plays a key role in the pathogenesis of hypertension.	Olmesartan Medoxomil	22-29	angiotensinogen	Homo sapiens	46-60
18547134-1	2008	Olmesartan medoxomil (Olmetec, Benicar) is an angiotensin II type 1 (AT(1)) receptor antagonist (angiotensin receptor blocker [ARB]) that inhibits the actions of angiotensin II on the renin-angiotensin-aldosterone system, which plays a key role in the pathogenesis of hypertension.	Olmesartan Medoxomil	22-29	angiotensinogen	Homo sapiens	162-176
17192125-7	2006	In a monkey atherosclerotic model, a 3-D intravascular ultrasound analysis of aortas showed that serum levels of MCP-1 and the degree of intimal hyperplasia were significantly lower after treatment with olmesartan medoxomil than before treatment.	Olmesartan Medoxomil	203-223	C-C motif chemokine ligand 2	Homo sapiens	113-118
17163232-2	2006	This trial investigated the possibility of pharmacokinetic interactions between the AT1 receptor antagonist olmesartan medoxomil and the thiazide diuretic hydrochlorothiazide in healthy subjects.	Olmesartan Medoxomil	108-128	angiotensin II receptor type 1	Homo sapiens	84-87
16183779-1	2005	In the present study, we investigated the esterase-like activity of human serum albumin (HSA) and the mechanism by which it hydrolyzes, and thereby activates, olmesartan medoxomil (CS-866), a novel angiotensin II receptor antagonist.	Olmesartan Medoxomil	181-187	albumin	Homo sapiens	74-87
12871826-2	2003	We studied the effect of a new angiotensin II type 1 (AT(1)) receptor antagonist, olmesartan medoxomil (olmesartan), on the fibrogenic responses in rat hepatic stellate cells (HSCs) and liver fibrogenesis.	Olmesartan Medoxomil	82-102	angiotensinogen	Rattus norvegicus	31-45
16321616-2	2005	In this randomized double-blind study we investigated renin-angiotensin system blockade obtained with 3 doses of olmesartan medoxomil (20, 40, and 80 mg every day) in 30 normal subjects and compared it with that obtained with lisinopril alone (20 mg every day) or combined with olmesartan medoxomil (20 or 40 mg).	Olmesartan Medoxomil	113-133	renin	Homo sapiens	54-59
16143317-2	2005	The aim of the present study was to determine the effect of chronic oral treatment with a new angiotensin II type 1 (AT(1)) receptor antagonist, RNH-6270 (the active form of olmesartan medoxomil), on cardiovascular responses to excitatory amino acids in the RVLM of SHR.	Olmesartan Medoxomil	174-194	angiotensinogen	Rattus norvegicus	94-108
14764070-9	2004	Angiotensin II receptor blockade with CS-866 (1 mg kg-1 day-1) prevented cardiac hypertrophy, PKC translocation and ERK1/2 activation in SNx rats without significant changes in blood pressure.	Olmesartan Medoxomil	38-44	angiotensinogen	Rattus norvegicus	0-14
14764070-9	2004	Angiotensin II receptor blockade with CS-866 (1 mg kg-1 day-1) prevented cardiac hypertrophy, PKC translocation and ERK1/2 activation in SNx rats without significant changes in blood pressure.	Olmesartan Medoxomil	38-44	protein kinase C, alpha	Rattus norvegicus	94-97
14764070-9	2004	Angiotensin II receptor blockade with CS-866 (1 mg kg-1 day-1) prevented cardiac hypertrophy, PKC translocation and ERK1/2 activation in SNx rats without significant changes in blood pressure.	Olmesartan Medoxomil	38-44	mitogen activated protein kinase 3	Rattus norvegicus	116-122
14620930-0	2003	A newly developed angiotensin II type 1 receptor antagonist, CS866, promotes regression of cardiac hypertrophy by reducing integrin beta1 expression.	Olmesartan Medoxomil	61-66	angiotensin II receptor, type 1b	Rattus norvegicus	18-48
14620930-0	2003	A newly developed angiotensin II type 1 receptor antagonist, CS866, promotes regression of cardiac hypertrophy by reducing integrin beta1 expression.	Olmesartan Medoxomil	61-66	integrin subunit beta 1	Rattus norvegicus	123-137
12477969-4	2002	MATERIALS AND METHODS: In this study we compared the effects of CS-866, a new angiotensin II type 1 receptor antagonist, to that of an ACE inhibitor, temocapril hydrochloride, on the development and progression of diabetic nephropathy using Otsuka Long-Evans Tokushima fatty rats, a type II diabetes mellitus model animal.	Olmesartan Medoxomil	64-70	angiotensin II receptor, type 1b	Rattus norvegicus	78-108
12503943-1	2003	OBJECTIVE: To review the pharmacology, pharmacokinetics, efficacy, and adverse effects of olmesartan medoxomil, an angiotensin II receptor antagonist for the treatment of hypertension.	Olmesartan Medoxomil	90-110	angiotensinogen	Homo sapiens	115-129
12231564-9	2002	COX-2 protein expression and superoxide production were increased in the aortas of aged rats and were also attenuated by treatment with temocapril or CS-866.	Olmesartan Medoxomil	150-156	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	0-5
9488244-0	1997	Blood pressure and endocrine effects of single doses of CS-866, a novel angiotensin II antagonist, in salt-restricted hypertensive patients.	Olmesartan Medoxomil	56-62	angiotensinogen	Homo sapiens	72-86
11787997-0	2001	Angiotensin II type-1 receptor antagonist, CS-866, reduces blood pressure without affecting glucose/insulin metabolism in cholesterol-fed rabbits.	Olmesartan Medoxomil	43-49	type-1 angiotensin II receptor	Oryctolagus cuniculus	0-30
11787997-1	2001	CS-866 is an angiotensin II type-1 receptor antagonist, the effects of which on systolic blood pressure (BP) and glucose/insulin metabolism are investigated under hyperlipidaemic conditions produced by cholesterol feeding.	Olmesartan Medoxomil	0-6	type-1 angiotensin II receptor	Oryctolagus cuniculus	13-43
11132603-3	2000	DESIGN: We studied the aortas of control rats and others receiving L-NAME or L-NAME plus an angiotensin II type 1 receptor antagonist (CS-866).	Olmesartan Medoxomil	135-141	angiotensin II receptor, type 1b	Rattus norvegicus	92-122
9488244-9	1997	CONCLUSION: The new Ang II receptor antagonist CS-866 is effective and well tolerated.	Olmesartan Medoxomil	47-53	angiotensinogen	Homo sapiens	20-26
8566137-0	1995	Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonist.	Olmesartan Medoxomil	16-22	angiotensinogen	Rattus norvegicus	43-57
9101313-8	1997	Three-day treatment with CS866, an AT1 receptor antagonist, and temocapril, an angiotensin-converting enzyme inhibitor, suppressed AT1 receptor expression in the rat adrenal cortex, but not in the heart or adrenal medulla.	Olmesartan Medoxomil	25-30	angiotensin II receptor, type 1a	Rattus norvegicus	35-38
9101313-8	1997	Three-day treatment with CS866, an AT1 receptor antagonist, and temocapril, an angiotensin-converting enzyme inhibitor, suppressed AT1 receptor expression in the rat adrenal cortex, but not in the heart or adrenal medulla.	Olmesartan Medoxomil	25-30	angiotensin II receptor, type 1a	Rattus norvegicus	131-134
8566137-4	1995	In conscious rats, intravenously injected RNH-6270 inhibited angiotensin II-induced pressor responses in a dose-dependent manner, and orally administered CS-866 produced a long-lasting inhibition of angiotensin II pressor responses.	Olmesartan Medoxomil	154-160	angiotensinogen	Rattus norvegicus	199-213
8566137-6	1995	These results demonstrate that RNH-6270 is a potent and AT1-selective angiotensin receptor antagonist and that, after oral administration, CS-866 has a long-lasting angiotensin II inhibitory action which is not affected by drug metabolizing enzymes in the liver.	Olmesartan Medoxomil	139-145	angiotensinogen	Rattus norvegicus	165-179
12697251-10	2003	These effects of ANGII were almost completely blocked by the ATR1 antagonist, CS-866.	Olmesartan Medoxomil	78-84	angiotensinogen	Rattus norvegicus	17-22
33191089-1	2021	In the present study, the biodistribution of self-microemulsifying drug delivery system of hydrophobic olmesartan medoxomil (OM-SMEDDS) was determined by labeling with a fluorescent dye VivoTag 680 XL and Xenolight  DiR.	Olmesartan Medoxomil	103-123	arginine vasopressin receptor 2	Mus musculus	216-219